Diagnostic tests for foot-and-mouth disease (FMD) include the detection of antibodies 17 against either the viral non-structural proteins or the capsid. The detection of antibodies against 18 the structural proteins (SP) of the capsid can be used to monitor seroconversion in both infected 19 and vaccinated animals. However, SP tests need to be tailored to the individual FMD virus 20 serotype and their sensitivity performances may be affected by antigenic variability within each 21 serotype and mismatching between tests reagents. As a consequence, FMD Reference 22 Laboratories need to maintain contingency to employ multiple type-specific assays for large-23 scale serological surveillance and post-vaccination monitoring in the event of FMD outbreaks. 24 In this study, a highly conserved region in the N terminus of FMDV capsid protein VP2 (VP2N) 25 was characterised using a panel of intertypic-reactive monoclonal antibodies. This revealed a 26 universal epitope in VP2N which could be used as a peptide antigen to detect FMDV-specific 27 antibodies against all types of the virus. A VP2-peptide ELISA (VP2-ELISA) was optimised 28 using experimental and reference antisera from immunized, convalescent and negative animals 29 (n=172). The VP2-ELISA is universal, simple and provided sensitive (98.6 %) and specific 30 (93%) detection of antibodies to all FMDV strains used in this study. We anticipate that this 31 SP test could have utility for sero-surveillance during virus incursions in FMD-free countries 32 and as an additional screening tool to assess FMD virus circulation in endemic countries. 33 34 Keywords: FMDV, conserved capsid epitope, ELISA, diagnosis, serology. 35 36 37 Foot-and-mouth disease (FMD) is an economically devastating viral disease of cloven-38 hoofed animals with a global distribution. It limits access to markets for developing countries 39 and outbreaks in otherwise FMD-free countries are expensive to control (as in the UK in 2001, 40 Japan in 2010 and the Republic of Korea in 2010 and 2011) [1, 2]. FMD virus (FMDV) is a 41 single-stranded, positive-sense, RNA virus belonging to the genus Aphthovirus in the family 42 Picornaviridae. The virus exists as seven serotypes (O, A, C, Asia 1, South African Territories 43 (SAT)1, SAT2 and SAT3) as well as numerous and constantly evolving strains showing a 44 spectrum of antigenic diversity.
Introduction

SDS-PAGE and western blot
Initial tests to verify the reactivity in western blot of each mAb with the homologous partially 145 purified strain were performed as previously described [21] . Later on, the cross-reactivity of 146 one representative mAb (4A3) with all FMDV serotypes was confirmed as follows. 147 Virus lysates from IBRS-2 cells infected cells with different FMDV serotypes were denatured 148 and reduced by heating at 95°C for 5min in Red Loading Buffer and DTT (NEB). The samples 149 were resolved through 12% Tris-glycine gels and transferred to nitrocellulose membrane 150 (0.45μM, GE Healthcare) using a Mini-Protean tetra cell (BioRad). Membranes were placed in 151 blocking buffer (20mM Tris, 150mM NaCl pH7.6 with 0.1% v/v tween-20 (TBS-T) with 1% 152 bovine serum albumin (BSA) w/v (Melford)) for 1h at RT followed by incubation with 153 hybridomas supernatants (mAbs) and anti-mouse HRP-conjugated secondary antibody (Dako)
(1/5000 in blocking buffer) in sequence for 1h at RT. Each incubation was separated by cycles 155 of three washings with TBS-T. West Pico chemiluminescent substrate (Thermo Fisher 156 Scientific, UK) was added to the membrane and exposures of the membrane were collected 157 and visualised using a G: Box Chemi XX6 (Syngene). blocking buffer (1% w/v BSA in PBS-T) at 37°C for 1h, and incubated either with 100μl of 180 mAb (hybridoma supernatants, 1/5) or bovine sera (diluted 1:50 to 1 in 400 in blocking 181 buffer) at 37°C for 1h. Antibody binding was detected by incubation at 37°C for 1h with anti-capsid antibodies. The sensitivity of the VNT, LPBE and SPCE are dependent on close 250 antigenic match between reagents used (virus/antigen and antibodies) and the serum sample 251 being tested. Therefore, the data from VNT and LPBE were subdivided into groups carried 252 out with homologous (same virus used to vaccinate or infect the animal) or heterologous 253 (same serotype but strain different than those used to vaccinate or infect the animal) reagents.
254
The data obtained with PrioCHECK kits was only available for samples from infections with 255 serotypes O, A and Asia 1.
256
As mentioned above, the VP2 ELISA data (Fig.3a ) contained a single false negative 257 equivalent to a sensitivity of 98.6%. In comparison, the homologous VNT data (n=37) had no 258 false negatives (sensitivity of 100%) while the heterologous VNT data (n=72) had a 259 sensitivity of 73.2% ( Fig.3b and Table 2 ). Similarly, the homologous LPBE data (n=30) had 260 no false negatives (sensitivity of 100%) and the heterologous LPBE data (n=72) had several 261 false negatives (sensitivity of 93.0%) ( Fig.3c and Table 2 ). The SPCE data (n=72) had a 262 single false negative (sensitivity of 98.6%) ( Fig. 3d and Table 2 ) and the PrioCHECK data 263 (n=29) had two false negatives (sensitivity of 93.1%) ( Fig. 3d and Table 2 ).
264
The single false negative sample (A Eritrea 3/98-41dpv) in the VP2 ELISA was also a false 265 negative in both the heterologous VNT (log titer =1.04) and heterologous LPBE (log 266 titre=1.6), but was positive in homologous VNT (log titer of 2.06) and weakly positive in the 267 SPCE (52 % inhibition) and PrioCHECK (65 % inhibition).
268
Overall these results show that the VP2 ELISA detected antibody to all serotypes and the OD 269 values may provide an estimate of the level of antibodies. The sensitivity of the new test 270 resulted equivalent to or better than PrioCHECK kits and SPCE; sensitivity was significantly 271 higher than LPBE and VNT when such assays are carried out with heterologous reagents. Fig 1. FMDV heterotypic-reactive mAbs recognise the N terminus of VP2. (a) 
333
Overlapping peptides representing the VP2 N-terminal 45 amino acids. The (K)6 denotes to 334 addition of 6 lysine residues at the C-terminus of the peptide to increase peptide solubility. 
